Two Drug Companies Admit to Price-Fixing for Nortriptyline

Alissa Healthcare Research and Pfizer subsidiary King Pharmaceuticals admitted they engaged in price-fixing following an investigation by the U.K.’s Competition and Markets Authority (CMA).

The two companies confessed that they broke the country’s competition laws when they shared “strategic and competitively-sensitive information” with each other between 2015 and 2017 in order to artificially keep up the prices of the antidepressant nortriptyline.

The CMA is still investigating another firm, Lexon, for its alleged involvement in the scheme, but it has denied any wrongdoing.